These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17631131)

  • 21. Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
    Yuan Y; Hunt RH
    Curr Pharm Des; 2007; 13(22):2237-47. PubMed ID: 17691997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.
    Sikes DH; Agrawal NM; Zhao WW; Kent JD; Recker DP; Verburg KM
    Eur J Gastroenterol Hepatol; 2002 Oct; 14(10):1101-11. PubMed ID: 12362101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lumiracoxib in the management of osteoarthritis and acute pain.
    Bannwarth B; Bérenbaum F
    Expert Opin Pharmacother; 2007 Jul; 8(10):1551-64. PubMed ID: 17661736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
    Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
    Chan FK; Hung LC; Suen BY; Wu JC; Lee KC; Leung VK; Hui AJ; To KF; Leung WK; Wong VW; Chung SC; Sung JJ
    N Engl J Med; 2002 Dec; 347(26):2104-10. PubMed ID: 12501222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.
    Hawkey CJ; Ell C; Simon B; Albert J; Keuchel M; McAlindon M; Fortun P; Schumann S; Bolten W; Shonde A; Hugot JL; Yu V; Arulmani U; Krammer G; Rebuli R; Toth E
    Clin Gastroenterol Hepatol; 2008 May; 6(5):536-44. PubMed ID: 18242145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
    Taha AS; Hudson N; Hawkey CJ; Swannell AJ; Trye PN; Cottrell J; Mann SG; Simon TJ; Sturrock RD; Russell RI
    N Engl J Med; 1996 May; 334(22):1435-9. PubMed ID: 8618582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.
    Solomon DH; Husni ME; Libby PA; Yeomans ND; Lincoff AM; Lϋscher TF; Menon V; Brennan DM; Wisniewski LM; Nissen SE; Borer JS
    Am J Med; 2017 Dec; 130(12):1415-1422.e4. PubMed ID: 28756267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.
    Stricker K; Yu S; Krammer G
    BMC Musculoskelet Disord; 2008 Sep; 9():118. PubMed ID: 18778469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
    Laine L; Curtis SP; Langman M; Jensen DM; Cryer B; Kaur A; Cannon CP
    Gastroenterology; 2008 Nov; 135(5):1517-25. PubMed ID: 18823986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers.
    Sostek MB; Fort JG; Estborn L; Vikman K
    Curr Med Res Opin; 2011 Apr; 27(4):847-54. PubMed ID: 21319944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
    Hawkey CC; Svoboda P; Fiedorowicz-Fabrycy IF; Nasonov EL; Pikhlak EG; Cousin M; Gitton X; Hoexter G
    J Rheumatol; 2004 Sep; 31(9):1804-10. PubMed ID: 15338504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study.
    Dong YH; Chang CH; Wu LC; Hwang JS; Toh S
    Br J Clin Pharmacol; 2018 May; 84(5):1045-1056. PubMed ID: 29468706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group.
    Graham DY; White RH; Moreland LW; Schubert TT; Katz R; Jaszewski R; Tindall E; Triadafilopoulos G; Stromatt SC; Teoh LS
    Ann Intern Med; 1993 Aug; 119(4):257-62. PubMed ID: 8328732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain.
    Kyle C; Zachariah J; Kinch H; Ellis G; Andrews C; Adekunle F
    Int J Clin Pract; 2008 Nov; 62(11):1684-92. PubMed ID: 19143855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
    Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
    Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.